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ABSTRACT  23 
Aims/hypothesis: Type 2 diabetes is more prevalent in Black African than White European 24 
populations although, paradoxically, they present with lower visceral fat, which has a known 25 
association with insulin resistance. Insulin resistance occurs at a tissue specific level however no 26 
study has simultaneously compared whole body, skeletal muscle, hepatic and adipose tissue insulin 27 
sensitivity between Black and White men. We hypothesised greater hepatic and adipose tissue insulin 28 
sensitivity in Black African (BAM) compared to White European men (WEM) with early type 2 29 
diabetes, due to reduced visceral fat.  30 
Methods: Eighteen BAM and 15 WEM with type 2 diabetes, matched for BMI and age, underwent a 2 31 
stage hyperinsulinaemic-euglycaemic clamp with glucose and glycerol stable isotope tracers to assess 32 
tissue specific insulin sensitivity and a magnetic resonance imaging scan to assess body composition.  33 
Results: We found no ethnic differences in whole body, skeletal muscle, hepatic or adipose tissue 34 
insulin sensitivity between BAM and WEM. This finding occurred in the presence of lower visceral 35 
fat in BAM (3.72 vs 5.68 kg [mean difference -1.96, 95% confidence interval -3.30, 0.62]; p= 0.01). 36 
There was an association between skeletal muscle and adipose tissue insulin sensitivity in WEM that 37 
was not present in BAM (r=0.78, p<0.01 vs r=0.25 p=0.37).  38 
Conclusions/interpretation: Our data suggest that in type 2 diabetes there are no ethnic differences in 39 
whole body, skeletal muscle, hepatic and adipose tissue insulin sensitivity between Black and White 40 
men despite differences in visceral adipose tissue, and that impaired lipolysis may not be contributing 41 
to skeletal muscle insulin resistance in men of Black African ethnicity.  42 
Keywords: adipose insulin sensitivity, Black African, ethnicity hepatic insulin sensitivity, insulin 43 
sensitivity, isotope, lipolysis, skeletal muscle insulin sensitivity, tracer, type 2 diabetes, visceral fat  44 
Abbreviations 45 
BSA - Body surface area 46 
BAM - Black African Men 47 
CRF - Clinical research facility 48 
MRI - Magnetic resonance imaging 49 
Ra - Rate of appearance 50 
Rd - Rate of disappearance  51 
SAT - Subcutaneous adipose tissue 52 
SM – Skeletal muscle 53 
TTR - Tracer-to-tracee ratio 54 
VAT - Visceral adipose tissue 55 
WEM - White European Men  56 
Research in context  57 
What is already known about this subject? (maximum of 3 bullet points) 58 
• Populations of Black African ancestry are at higher risk of developing type 2 diabetes 59 
compared to their White European counterparts despite displaying lower visceral fat, hepatic 60 
fat and a favourable blood lipid profile. 61 
• The pathophysiology of type 2 diabetes involves insulin resistance which occurs at multiple 62 
sites including the skeletal muscle, liver and adipose tissue.  63 
What is the key question? (one bullet point only; formatted as a question) 64 
• Do Black West African men with early type 2 diabetes present with greater hepatic and 65 
adipose tissue insulin sensitivity?  66 
What are the new findings? (maximum of 3 bullet points) 67 
• During early type 2 diabetes, there are no ethnic differences in skeletal muscle, hepatic and 68 
adipose tissue insulin sensitivity despite greater skeletal muscle and reduced visceral fat in 69 
Black West African men.  70 
• There appears to be an independent relationship between skeletal muscle insulin resistance 71 
and adipose tissue resistance to lipolysis in Black West African men.  72 
How might this impact on clinical practice in the foreseeable future? (one bullet point only) 73 
• Using prevention and treatment strategies which target adipose tissue function may not 74 
produce the same impact in Black African and White European populations.  75 
INTRODUCTION 76 
Populations of Black African ancestry are disproportionately affected by type 2 diabetes compared to 77 
White Europeans [1]. The pathophysiological processes of type 2 diabetes are well documented and 78 
include beta-cell dysfunction, ectopic fat deposition and insulin resistance of the liver, skeletal muscle 79 
and adipose tissue [2, 3]; the use of stable isotopes has enabled measurement of these tissue specific 80 
sites of insulin resistance [4]. Black populations typically display lower visceral adipose tissue (VAT) 81 
and hepatic fat deposition and a more favourable blood lipid profile [5]. Visceral fat has been positively 82 
associated hepatic and adipose tissue insulin resistance in diabetes and normal glucose tolerance [6]. 83 
The lower VAT exhibited in Black populations suggests there may be ethnic distinctions in the 84 
pathophysiology of type 2 diabetes. There have been several studies comparing tissue specific insulin 85 
resistance in vivo, using the ‘gold standard’ hyperinsulinaemic-euglycaemic clamp and stable isotopes, 86 
in healthy populations of Black and White ethnicity. These have been conducted primarily, although 87 
not exclusively, in women and adolescents but have not produced a consistent picture [7-20]. Gender 88 
differences in body composition have shown women to express greater central and overall body fat 89 
[21]. Accordingly, a gender distinction in the type 2 diabetes phenotype has been shown in Black 90 
Africans, whereby men display greater insulin sensitivity compared to women [22]. The inconsistences 91 
in the findings from adolescent and female populations likely stem from differences in methodologies 92 
and participant body composition. Ethnic comparisons in people with type 2 diabetes are required to 93 
inform therapeutic decisions however, they are also limited to adolescent and female populations [23, 94 
24]. Peripheral insulin stimulated glucose disposal has been shown to be similar in diabetic adolescents 95 
[23] but to date no study has compared this in diabetic Black and White adults using stable isotope 96 
methods. Studies assessing ethnic differences in hepatic insulin sensitivity in type 2 diabetes are few; 97 
studies of basal endogenous glucose production have shown no difference in adolescents [23] but no 98 
studies have assessed insulin stimulated suppression of endogenous glucose production and there have 99 
been no studies performed in adults with type 2 diabetes. In vivo assessment of adipose tissue insulin 100 
sensitivity in type 2 diabetes has been more limited; lower basal free fatty acid release has been reported 101 
in Black women [24] however no study has assessed insulin stimulated suppression of fatty acid release. 102 
To date, no single study has undertaken a comprehensive ethnic comparison of whole body, peripheral, 103 
hepatic and adipose tissue sensitivity to insulin using the same study cohort and methodology.  104 
We aimed to compare tissue specific sites of insulin sensitivity between Black (west) African (BAM) 105 
and White European men (WEM) with early type 2 diabetes using the hyperinsulinaemic-euglycaemic 106 
clamp with stable isotopes, and to investigate associations between sites of insulin resistance by 107 
ethnicity. We hypothesise that in early type 2 diabetes, BAM men will have greater hepatic and adipose 108 
tissue insulin sensitivity due to lower VAT deposition compared to their White European counterparts. 109 
  110 
METHODS 111 
The study was conducted at the Clinical Research Facility (CRF), King’s College London, UK and 112 
approved by the London Bridge National Research Ethics Committee (12/LO/1859); all participants 113 
provided informed consent. The data were collected as part of the South London Diabetes and Ethnicity 114 
Phenotyping (Soul-Deep) study; recruitment and data collection took place April 2013-January 2015 115 
[25, 26].   116 
Participants 117 
Black West African (BAM) or White European (WEM) (self-declared, confirmed by grandparental 118 
birthplace) men, aged 18-65 years, BMI 25-35 kg/m2, with a diagnosis of type 2 diabetes within 5 years, 119 
treated with lifestyle advice ± metformin, with HbA1c ≤63·9 mmol/mol (<8%) were recruited from 120 
South London primary care practices and selected to match for age and BMI. Participants were deemed 121 
ineligible if: treated with thiazolidinedione, insulin, chronic oral steroids, beta-blockers; serum 122 
creatinine >150 mmol/l; serum alanine transaminase level >2.5-fold above the upper limit of the 123 
reference range; positive auto-antibodies for anti-insulin, anti-GAD or anti-A2; sickle cell disease (trait 124 
permitted); or using medications believed to affect the outcome measures. Participants completed a 125 
comprehensive medical screening before study entry.  126 
Study design 127 
Participants arrived at the CRF in a fasted state, having refrained from eating or drinking anything other 128 
than water from 10pm the night prior. Participants were instructed to refrain from strenuous physical 129 
activity in the 48 hours preceding the visit, refrain from consuming alcohol in the 24 hours preceding 130 
the visit, and to consume a standardised diet the day prior (~50% of calories from carbohydrate, evenly 131 
spread throughout the day, with no more than 30% of daily carbohydrate consumed in the evening 132 
meal). Participants on metformin were instructed to cease taking it for 7 days prior to the visit. 133 
Hyperinsulinaemic-euglycaemic clamp assessment of whole body, skeletal muscle, hepatic and 134 
adipose tissue insulin sensitivity 135 
Upon arrival, participants were weighed in light clothing and their body surface area calculated using 136 
the Mosteller formula. A cannula was inserted into an antecubital fossa vein to infuse stable isotopically 137 
labelled tracers, 20% dextrose and insulin (Actrapid, Novo Nordisk, Denmark) bound to albumin. A 138 
second cannula was inserted retrogradely into the dorsum of the hand, which was placed in a hand 139 
warming unit, to achieve arterialised venous blood samples. A baseline blood sample determined the 140 
participant’s fasting plasma glucose; if above 5 mmol/l a sliding scale insulin infusion was used to lower 141 
the circulating glucose to 5 mmol/l. At time point -120 minutes, a primed (2.0 mg/kg), continuous (0.02 142 
mg kg-1 min-1) infusion of [6,6 2H2]-glucose and a primed (0.12 mg/kg), continuous (0.0067 mg kg-1 143 
min-1) infusion of [2H5]-glycerol (CK Gases Ltd, UK) were initiated [27]. Basal state blood samples 144 
were taken between -30 and 0 minutes. After infusion of the tracers for 120 minutes (basal period), a 2-145 
stage hyperinsulinaemic-euglycaemic clamp procedure was started at time point 0 minutes, and 146 
continued for 4 hours (during which the infusion of [6,6 2H2]-glucose was continued however, the 147 
infusion of [2H5]-glycerol was stopped just prior to beginning the stage 2 insulin infusion). Insulin was 148 
infused at a rate of 10 mU m-2 BSA min-1 (initiated with a priming dose of 30 mU m-2 BSA min-1 for 3 149 
minutes and then 20 mU m-2 BSA min-1 for 4 minutes) during stage 1 (0 – 120 minutes) and at a rate of 150 
40 mU m-2 BSA min-1 (initiated with a priming dose of 120 mU m-2 BSA min-1 for 3 minutes and then 151 
80 mU m-2 BSA min-1 for 4 minutes) during stage 2 (120 – 240 minutes) [19, 28]. Euglycaemia (5 152 
mmol/l) was maintained by variable infusion of 20% dextrose, which was enriched with [6,6 2H2]-153 
glucose (8 mg/g glucose with low dose insulin and 10 mg/g with high dose insulin) to ensure a constant 154 
glucose tracer-to-tracee ratio (TTR). Plasma glucose readings were taken every 5 minutes, using an 155 
automated glucose analyser, to inform adjustment of the glucose infusion rate. Hepatic and adipose 156 
tissue insulin sensitivity were evaluated in the low dose insulin infusion, whole body and peripheral 157 
(primarily skeletal muscle) insulin sensitivity were evaluated in the high dose insulin infusion. Blood 158 
samples were collected before beginning the tracer infusions to determine baseline enrichment of 159 
glucose and glycerol. At time points -30, -20, -10 and 0 minutes baseline blood samples were collected, 160 
followed by sampling at 30, 60, 90, 100, 110, 120, 150, 180, 210, 220, 230 and 240 minutes for the 161 
assessment of plasma glucose and glycerol concentrations and enrichments, insulin and NEFA 162 
concentrations. 163 
Magnetic resonance imaging  164 
Participants attended the MRI unit of Guy’s Hospital, King’s College London, for the assessment of 165 
subcutaneous (SAT) and visceral adipose tissue (VAT), and skeletal muscle (SM) mass. Scanning was 166 
performed on a 1.5T Siemens scanner to acquire MRI images from the neck to the knee (excluding the 167 
arms). Participants lay supine with body coils secured on the scanned body area.  168 
For each participant, the MRI scan produced 320 contiguous axial fat and water images each 3mm apart. 169 
The Dixon-MRI T1-weighted spin-echo sequence includes an echo time of 4.77ms for the in-phase 170 
images, 2.39ms for the out-of-phase images and a repetition time of 6.77ms. MRI images were analysed 171 
using a semi-automated method carried out by Klarismo Ltd to quantify SAT and SM mass volumes in 172 
all images between the neck and knee region and VAT volume in the whole abdominal cavity. 173 
Analyses of samples 174 
Plasma glucose concentration was measured by automated glucose analyser (Yellow Spring 175 
Instruments, 2300 STAT Glucose Analyzer, Ohio, USA). Serum insulin concentration was measured 176 
by immunoassay using chemiluminescent technology (ADVIA Centaur System, Siemens Healthcare 177 
Ltd. Camberly, UK). Plasma NEFA were measured by an enzymatic colorimetric assay (Wako 178 
Diagnostics, Richmond, VA, USA) on an automated clinical chemistry analyser (ILab 650, Instrument 179 
Laboratories, Holliston, MA, USA). The glucose and glycerol enrichment (TTR) in plasma were 180 
measured by gas chromatography-mass spectrometry on an Agilent GCMS 5975C MSD (Agilent 181 
Technologies, Wokingham, UK) using selected ion monitoring. The isotopic enrichment of glucose was 182 
determined as the penta–O-trimethylsilyl-D-glucose-O-methyloxime derivative [29]. The isotopic 183 
enrichment of plasma glycerol was determined as the tert-butyl trimethylsilyl (tBDMS) glycerol 184 
derivative [30].   185 
Calculations 186 
- Total glucose disposal rate (M value in mg kg-1 min-1); was calculated as a measure of whole 187 
body insulin sensitivity. This was computed as the mean of the glucose infusion rate, corrected 188 
for any change in measured plasma glucose concentration, during the final 30 mins of the high 189 
dose insulin infusion [28]. Additionally, M was adjusted for mean insulin concentration (M/I). 190 
- Peripheral glucose utilisation (glucose rate of disappearance, Rd mol kg-1 min-1), endogenous 191 
glucose production (glucose rate of appearance, Ra mol kg-1 min-1) and whole body lipolysis 192 
(glycerol rate of appearance, Ra mol kg-1 min-1) were calculated using Steele’s non-steady 193 
state equations modified for stable isotopes assuming a volume distribution of 22% body weight 194 
[31]. Calculation of glucose kinetics was modified for inclusion of [6,6-2H2]-glucose in the 195 
dextrose infusion [32]. Before calculation of glucose and glycerol kinetics, enrichment and 196 
concentrations were smoothed using optical segments analysis [33].  197 
- Peripheral glucose utilisation (glucose Rd) was calculated during the basal state and the final 198 
30 minutes of the high dose insulin infusion. We used the percentage increase in glucose Rd 199 
from basal to the high dose insulin infusion as a measure of skeletal muscle insulin sensitivity 200 
[34].  201 
- Endogenous glucose production (glucose Ra) was calculated by subtracting the exogenous 202 
glucose infusion rate from total glucose Ra. Glucose Ra was calculated during the basal state 203 
and during final 30 minutes of the low dose insulin infusion. Percentage suppression of glucose 204 
Ra from basal to the low dose insulin infusion was calculated as a measure of hepatic insulin 205 
sensitivity [35].  206 
- Whole body lipolysis (glycerol Ra) was calculated during the basal state and during the final 207 
30 minutes of the low dose insulin infusion. Percentage suppression of glycerol Ra from basal 208 
to the low dose insulin infusion was calculated as a measure of adipose tissue insulin sensitivity 209 
[34].  210 
- The area under the curve for plasma glucose, insulin and NEFA concentrations during the clamp 211 
were calculated using the trapezium rule.  212 
Statistics 213 
All variables were checked for normality using the Shapiro-Wilks test and non-normally distributed 214 
variables were transformed (log 10) for analysis. Normally-distributed data are expressed as mean (SD), 215 
log-normal data were back transformed to give geometric mean and 95% CI and data which remained 216 
skewed after log transformation are expressed as median (IQR). Ethnic differences between means were 217 
determined using the independent samples t-test for normally distributed data and Mann-Whitney U 218 
test for skewed data. Mean difference or the ratio of the geometric mean and 95% CI are presented 219 
where appropriate. Associations between insulin sensitivity measures and with VAT were tested using 220 
Pearson’s correlation coefficient. Multiple regression analyses were conducted to adjust for the effect 221 
of body composition (VAT and SM mass) on insulin sensitivity measures. Linear regression analysis 222 
was used to determine the impact of ethnicity (interaction) on the associations between insulin 223 
sensitivity measures.  p≤0.05 was considered statistically significant. Analyses were performed using 224 
SPSS software, version 22 (IBM Analytics, NY).   225 
RESULTS 226 
Participant characteristics 227 
The clinical characteristics of the participants are shown in Table 1. By design, the groups were not 228 
statistically different in age, weight and BMI. Waist circumference, BSA, SAT, number of years 229 
following diabetes diagnosis, HbA1c and the proportion of those treated with metformin were not 230 
different between ethnic groups. Mean VAT mass was 34.5% lower and mean SM mass was 11.9% 231 
greater in BAM (Table 1). 232 
Insulin sensitivity – whole body, skeletal muscle, hepatic and adipose tissue 233 
Basal plasma glucose (BAM; 5.89 (0.39) vs WEM; 5.71(0.63) mmol/l, p=0.38), insulin (BAM; 45.7 234 
(36.8, 56.7) vs WEM; 57.3 (39.5, 83.2) pmol/l, p=0.24) and NEFA (BAM; 0.48 (0.17) vs WEM; 0.55 235 
(0.18) mmol/l, p=0.30) were not different and there were no ethnic differences in plasma glucose 236 
(p=0.89), insulin (p=0.78) and NEFA (p=0.70) concentrations during the clamp (Fig. 1). Total glucose 237 
disposal rate (M), as a measure of whole body insulin sensitivity, did not differ between the ethnic 238 
groups (Table 2); the lack of significance continued after adjustment for mean insulin during the high 239 
dose insulin infusion (M/I- BAM; 0.030 (0.017) vs WEM; 0.026 (0.011) mg kg-1 min-1 pmol/l-1, p=0.46). 240 
Peripheral glucose utilisation (Glucose Rd) during the high dose insulin infusion (Table 2) and skeletal 241 
muscle insulin sensitivity (% increase in peripheral glucose utilisation) were also similar between ethnic 242 
groups (Fig. 2a: BAM; 203.5 (126.2) vs WEM; 166.3 (102.5), mean difference of 37.3%, 95% CI -55.6, 243 
130.1; p= 0.42).  Basal endogenous glucose production (glucose Ra) was similar between BAM and 244 
WEM and there were no ethnic differences in endogenous glucose production during the low dose 245 
insulin infusion (Table 2) or in hepatic insulin sensitivity (% suppression of endogenous glucose 246 
production) (Fig. 2b: BAM; -36.4 (19.7) vs WEM; -34.8 (20.7), mean difference of -1.61%, 95% CI -247 
17.7, 14.5; p=0.84). There was a trend towards lower basal whole body lipolysis (glycerol Ra) in BAM 248 
compared to WEM but this did not reach statistical significance (Table 2). There were no ethnic 249 
differences in lipolysis during the low dose insulin infusion or in adipose tissue insulin sensitivity (% 250 
suppression of lipolysis) (Fig. 2c: BAM; -37.2 (16.0) vs WEM; -37.5 (13.7), mean difference of 0.32%, 251 
95% CI -12.5, 13.1; p=0.96). After adjustment for VAT and skeletal muscle mass, we found no ethnic 252 
differences in whole body insulin sensitivity (mean difference; 0.95 mg kg-1 min-1, 95% CI -0.48, 2.37; 253 
p=0.18) or skeletal muscle insulin sensitivity (mean difference; 82.3%, 95% CI -23.1, 187.8; p=0.12). 254 
Similarly when we adjusted hepatic and adipose tissue insulin sensitivity for VAT we found no ethnic 255 
differences with a mean difference of 9.1%, 95% CI -9.8, 28.0; p= 0.33 and 8.4% 95% CI -5.7, 22.4; 256 
p=0.23, respectively. Correlation analysis of hepatic insulin sensitivity with VAT was only significant 257 
in BAM (BAM; r=-0.55 p=0.04, WEM; r=-0.23 p=0.50) and when we correlated VAT with adipose 258 
tissue insulin sensitivity we found no association in BAM (r=-0.13 p=0.66) but a trend towards an 259 
association in WEM (r=-0.60 p=0.09).  260 
Associations between tissue specific sites of insulin sensitivity  261 
As shown in Fig. 3a, we found a significant correlation between skeletal muscle (% increase in Rd) and 262 
hepatic insulin sensitivity (% suppression of Ra) in both ethnicities. We found no significant correlation 263 
between skeletal muscle and adipose tissue insulin sensitivity (% suppression of glycerol Ra) in BAM 264 
however there was a strong correlation in WEM (Fig. 3b). In both ethnicities, there were no significant 265 
correlations between hepatic and adipose tissue insulin sensitivity (Fig. 3c). We further explored the 266 
impact of ethnicity on these associations using regression analysis and found no significant ethnicity 267 
interaction for the impact of hepatic on skeletal muscle insulin sensitivity (p=0.82), or adipose tissue 268 
on skeletal muscle insulin sensitivity (p=0.26) or adipose tissue on hepatic insulin sensitivity (p=0.84).     269 
DISCUSSION 270 
To our knowledge this is the most comprehensive ethnic comparison of whole body, skeletal muscle, 271 
hepatic and adipose tissue insulin sensitivity in a single study between adults of Black African and 272 
White European ethnicity with early type 2 diabetes. We have found, in BAM and WEM matched for 273 
BMI and age, with early type 2 diabetes, comparable whole body, skeletal muscle, hepatic and adipose 274 
tissue insulin sensitivity despite lower visceral adipose tissue deposition and greater skeletal muscle 275 
mass in BAM. In addition, we have also shown ethnic differences in the associations between tissue 276 
specific sites of insulin sensitivity which adds to the concept of ethnic distinctions in type 2 diabetes 277 
pathophysiology.  278 
Lower visceral fat deposition has been extensively reported in Black populations compared to other 279 
ethnic groups [5] and we hypothesised that consequently BAM would exhibit greater adipose tissue and 280 
hepatic insulin sensitivity. Although our data did not show a significant relationship between adipose 281 
and hepatic insulin sensitivity and VAT which may be due to the sample size; we did detect lower VAT 282 
and a trend towards lower basal lipolysis in our BAM, which agrees with the majority of the literature. 283 
However, we did not find greater adipose tissue insulin sensitivity (even after adjustment for VAT) 284 
which contrasts with the findings of a study in Black women [14], notably this study used a lower 285 
insulin dose than ours and the women were free of type 2 diabetes which may explain some of the 286 
inconsistencies between our findings. Our men had been recently diagnosed with type 2 diabetes, thus 287 
pathophysiological changes may be present that are not seen in non-diabetic groups. Likewise, the 288 
presence of diabetes may be important in the lack of greater hepatic insulin sensitivity in our Black 289 
men, as per our hypothesis. Our findings agree with studies in adolescents [7, 10-13, 20, 23] and a single 290 
study in lean non-diabetic women [18] but do not agree with studies in obese non-diabetic women [17, 291 
19] suggesting that, in addition to glycaemic status, body composition may also play a role in the ethnic 292 
comparison. Our results were consistent after adjustment for VAT hence future studies controlling for 293 
other ectopic fat depots could help us to understand the impact of adiposity and ethnicity in type 2 294 
diabetes. 295 
Another finding from this study is the lack of ethnic differences in whole body or skeletal muscle insulin 296 
sensitivity, which remained even after we adjusted for differences in VAT and skeletal muscle mass. 297 
An extensive literature base exists in which Black populations are noted to exhibit pronounced insulin 298 
resistance compared to other ethnic groups, however, the majority of these studies have used methods 299 
which estimate, rather than directly measure, insulin sensitivity [36] and even in studies using the 300 
hyperinsulinaemic-euglycaemic clamp method, mixed results are reported [37]. Again, the type 2 301 
diabetes status of our participants is important here, as the presence of the diabetes may have attenuated 302 
any pre-morbid ethnic differences in insulin sensitivity. This suggestion is supported by the results from 303 
a large study of diabetic and non-diabetic populations [38] in which the intravenous glucose tolerance 304 
test was used to assess insulin sensitivity. While ethnic differences were present in the non-diabetic 305 
state [38], they were absent in type 2 diabetes [39], suggesting that by the end of the glucose tolerance 306 
spectrum ethnic differences in insulin sensitivity may have dissipated. It is also reasonable to propose 307 
that the adiposity status of our participants may explain the absence of ethnic differences in insulin 308 
sensitivity. We matched our ethnic groups for body mass index, their body weights were on average in 309 
the overweight and obese range, as typical for people with type 2 diabetes, hence the impact of excess 310 
adiposity may also have attenuated any ethnic differences, as discussed in other studies comparing 311 
ethnicity in populations with type 2 diabetes [23]. However, insulin sensitivity data, which have been 312 
stratified for obese and non-obese in type 2 diabetes, has also shown no ethnic differences [39] 313 
suggesting that our result is real and driven more by the presence of type 2 diabetes. In addition to 314 
obesity status, we were able to assess skeletal muscle mass which was found to be higher in BAM. 315 
Having the same whole body and skeletal muscle insulin sensitivity in the presence of greater skeletal 316 
muscle mass, and having the same hepatic and adipose sensitivity in the presence of reduced visceral 317 
fat, suggests that the BAM may be more insulin resistant when adjusted for lean mass [23, 40] however 318 
we did not find this and there may be other confounding factors such as muscle and hepatic lipid content 319 
which explain this finding, which we have not investigated here.  320 
Increased fatty acid release (lipolysis), which occurs during excess adiposity, particularly visceral 321 
adiposity, has been shown to impair glucose homeostasis through the process of lipotoxicity. The fatty 322 
acids impair insulin signalling and lead to skeletal and hepatic insulin resistance, contributing to the 323 
pathophysiology of type 2 diabetes [41-43]. We would therefore expect to see a significant relationship 324 
between lipolysis and both skeletal muscle and hepatic insulin sensitivity. Our data show a strong 325 
association between lipolysis and skeletal muscle insulin sensitivity in WEM, which was not present in 326 
BAM. This may suggest an independent relationship between insulin sensitivity of the adipose tissue 327 
to lipolysis and skeletal muscle glucose uptake in BAM and may imply that mechanisms other than 328 
lipotoxicity are central to the development of hyperglycaemia in BAM. We do, however, acknowledge 329 
that our regression analysis failed to support an impact of ethnicity on the relationship between lipolysis 330 
and skeletal muscle sensitivity, which may have been due to the small sample size in our study. 331 
Although we have not directly measured lipotoxocity, as this involves a combination of increased fatty 332 
acid availability and uptake into the muscle, the concept of an independent relationship between glucose 333 
and lipid metabolism is supported by a number of studies that have identified the presence of 334 
hyperglycaemia in the absence of pronounced ectopic fat, particularly visceral fat [26]. Further 335 
investigation on muscle lipid uptake, insulin signalling and ectopic fat deposition would help to improve 336 
our understanding of the impact of lipotoxicity on skeletal muscle insulin resistance in Black 337 
populations. 338 
The strengths of this study lie in our use of the hyperinsulinaemic-euglycaemic clamp with stable 339 
isotope infusions to directly assess and compare tissue specific insulin sensitivity in vivo in a single 340 
study [28]. In particular, the use of a glycerol tracer as opposed to a fatty acid tracer allows for a direct 341 
measure of fatty acid release because glycerol is not recycled back into triacylglycerol whereas fatty 342 
acids are [44]. Using a 2-stage hyperinsulinaemic-euglycaemic clamp allowed for a low and high dose 343 
insulin infusion to be applied, enabling quantification of suppression of endogenous glucose production 344 
and lipolysis, which is missed when only a high dose insulin infusion is used [45]. All of the studies 345 
assessing hepatic and skeletal insulin sensitivity in adolescents have used a single high dose insulin 346 
clamp in which endogenous glucose production is near maximally suppressed preventing assessment 347 
of suppression of endogenous glucose production. Our study is necessarily small due to the complexity 348 
of our protocol, however, it is comparable to other studies using these methodologies in type 2 diabetes 349 
[23, 24]. Furthermore, these data were collected as part of a larger study powered to investigate ethnic 350 
differences in beta-cell function (reported elsewhere [26]) and we acknowledge that our sample size 351 
may hinder the conclusions we can draw from these data. Whilst we made an effort to control the dietary 352 
intake prior to the metabolic assessments, which may have impacted on metabolism and insulin 353 
sensitivity, we did not undertake a formal analysis of adherence to this aspect of the protocol. We also 354 
must consider that the insulin dosage we used in our high dose stage may not have been sufficient to 355 
induce full suppression of endogenous glucose production for our most insulin resistant participants, 356 
however on average we achieved 80% suppression from basal.  357 
In conclusion, we have found that in early type 2 diabetes there are no ethnic differences in insulin 358 
sensitivity between BAM and WEM despite BAM having lower visceral fat and higher skeletal muscle 359 
mass. While adipose tissue lipolysis is strongly associated with skeletal muscle insulin sensitivity in 360 
WEM, there is less evidence for an association in BAM suggesting an independent relationship between 361 
glucose and lipid metabolism may exist within the development of type 2 diabetes in this ethnic group.   362 
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  512 
Table 1. Clinical characteristics of Black African and White European men with type 2 diabetes 513 
 Black African  
Men 
White European  
Men 
Sample size 
Black / White 
P 
Age (years) 54.0 (47.9, 60.2) † 59.0 (55.5, 62.5) † 18/15 0.51 
Weight (kg) 90.9 (9.3) 94.2 (11.6) 18/15 0.38 
Height (cm) 175.6 (7.6) 176.8 (5.8) 18/15 0.91 
BMI (kg/m2) 29.5 (2.7) 30.1 (2.7) 18/15 0.55 
Waist circumference (cm) 103.6 (8.4) 107.5 (8.8) 18/15 0.20 
Body surface area (m2) 2.08 (0.14) 2.13 0.15) 18/15 0.40 
Visceral adipose tissue mass (kg) 3.72 (1.07) 5.68 (2.43) 17/14 0.01 
Subcutaneous adipose tissue mass 
(kg) 
11.8 (3.9)  11.8 (2.6) 16/14 0.98 
Skeletal muscle mass (kg) 20.7 (2.5) 18.5 (3.0) 17/14 0.03 
Duration of diabetes (years) 3.0 (2.5, 3.6) † 3.0 (2.0, 4.0) † 18/15 0.74 
HbA1c (mmol/mol) 50.4 (7.5) 48.6 (7.8) 18/15 0.50 
Systolic blood pressure (mmHg) 138.4 (13.6) 131.8 (13.9) 18/15 0.18 
Diastolic blood pressure (mmHg) 86.9 (5.1) 82.9 (10.1) 18/15 0.19 
Total cholesterol (mmol/l) 4.17 (0.68) 4.30 (0.72) 18/15 0.61 
LDL-cholesterol (mmol/l) 2.37 (0.53) 2.29 (0.70) 18/15 0.71 
HDL-cholesterol (mmol/l) 1.19 (0.38) 1.24 (0.24) 18/15 0.66 
Triacylglycerol (mmol/l) 1.20 (0.95, 1.52) ‡ 1.58 (1.26, 1.97) ‡ 18/15 0.09 
Treated with metformin (%) 78 (n=14) 53 (n=8) 18/15 0.16 
 514 
Data expressed as mean (SD) for normally distributed data unless labelled †median 515 
(interquartile range) for skewed distributed data, ‡geometric mean (95% CI) for log transformed 516 
data or as percentage of subjects where required. P values were generated using an independent 517 
sample t-test for normally distributed data and Mann-Whitney U test for skewed data. Skeletal 518 
muscle mass was measured from neck to knee excluding arms.  519 
 520 
Table 2. Two-stage hyperinsulinemic-euglycemic clamp assessment of insulin sensitivity in Black African and White European men with type 2 diabetes 521 
 Basal Hyperinsulinemic-euglycemic clamp 






Mean difference or ratio 
of the geometric mean 
(95% CI) (BAM-WEM) 
(95% CI) 













(M; mg kg-1 min-1) 
 













(Ra; mol kg-1 min-
1) 
 
8.82 (1.49) 9.25 (1.66) -0.43 
(-1.69, 0.81) 
 




(glycerol Ra; mol 
kg1  min-1)  
1.51 (1.31, 1.75) 1.82 (1.55, 2.15) 0.83 
(0.67, 1.02) 




Data expressed as mean (SD) for normally distributed data and geometric mean (95% CI) for skewed data. M value and glucose Rd assessments were derived 523 
from the high dose insulin infusion (40 mU m-2 BSA min−1), glucose and glycerol Ra assessments were derived from the low dose insulin infusion (10 mU m-2 524 
BSA min−1) of the hyperinsulinaemic-euglycaemic clamp and at baseline. Rd, rate of disappearance; Ra, rate of appearance; EGP, endogenous glucose 525 
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  546 
FIGURE LEGENDS 547 
Figure 1: Plasma glucose (A), insulin (B) NEFA (C) concentrations for Black African () and White 548 
European men () with type 2 diabetes at baseline, low dose and high dose insulin infusion of the 549 
hyperinsulinaemic-euglycaemic clamp. Data expressed as mean (SEM) for each time point and glucose, 550 
insulin and NEFA area under the curve. 551 
Figure 2: Insulin mediated peripheral glucose uptake (A), suppression of endogenous glucose 552 
production (B) and suppression of lipolysis (C), calculated as percentage change from basal to the low 553 
or high dose insulin infusion. The difference in sample size from Table 2 is due to a small number of 554 
participants missing basal data due to the administration of a sliding scale insulin infusion to achieve 555 
euglycaemia 5mmol/l prior to beginning the clamp. 556 
Figure 3: Associations between tissue specific insulin sensitivity during the hyperinsulinaemic-557 
euglycaemic clamp in BAM and WEM men with early type 2 diabetes (A) peripheral (calculated as the 558 
percentage increased in glucose Rd from basal to high dose insulin infusion, 40 mU m-2 BSA min−1) 559 
and hepatic insulin sensitivity (calculated as the percentage suppression of glucose Ra from basal to 560 
low dose insulin infusion, 10 mU m-2 BSA min−1) (B) peripheral and adipose tissue insulin sensitivity 561 
(calculated as the percentage suppression of glycerol Ra from basal to low dose insulin infusion, 10 mU 562 
m-2 BSA min−1), and (C) hepatic and adipose tissue insulin sensitivity. Data expressed using Spearman’s 563 
correlation coefficient. Sample size: Black African n= 15, White European n= 12 (except adipose tissue 564 
insulin sensitivity analyses where n=10 for White European men). Black dots and black regression line, 565 
BAM; grey dots and grey regression line, WEM. 566 
 567 
